During the 1990's, physicians commonly prescribed HT for menopausal women because they thought that it would "protect women against heart disease and dementia" (Bee, 2012, pg.394). However, the perception of this therapy changed when a study was posted in 2002 by the Women's Health Initiative (Bee, 2012, pg. 394). The study by this organization showed that long-term use of estrogen or combined estrogen-progesterone HT greatly increased the risk of breast and ovarian cancers (Bee, 2012, pg.394). The Heart and Estrogen Replacement Study (HERS) showed that HT did not give women protection against cardiovascular disease (CD) (Bee, 2012, pg.394). Additionally, the study suggested that HT could have possibly increased the intensity of CD "among study participants who already had it" (Bee, 2012, pg. 394). Another source states that HT increases the risk of uterine cancer (WebMD, 2012, pg. 1). Finally, HT also increases the risk of blood clots and stroke (Mayo Clinic staff, 2012, pg.1). After these studies were published, the number of women taking part in HT significantly decreased (Bee, 2012, pg.394).
In spite of risks of HT, it does have benefits for women with menopause. However, the benefits of this therapy are few. Recent research has shown that HT only reduces hot flashes "and